Puma Biotechnology Inc. (PBYI)

25.22
0.25 0.98
NASDAQ : Health Technology
Prev Close 25.47
Open 25.48
Day Low/High 24.66 / 25.77
52 Wk Low/High 17.60 / 95.05
Volume 769.13K
Avg Volume 1.40M
Exchange NASDAQ
Shares Outstanding 38.13M
Market Cap 971.30M
EPS -7.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the European Patent Office has upheld the claims in Puma's licensed European patent (EP 2416774), which were being opposed by Hexal AG.

CONTROL Trial At SABCS

CONTROL Trial At SABCS

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma's drug neratinib at the 2017 San Antonio Breast Cancer Symposium (SABCS) that...

Puma Biotechnology And Specialised Therapeutics Asia Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Australia, New Zealand And South East Asia

Puma Biotechnology And Specialised Therapeutics Asia Enter Into Exclusive Licensing Agreement To Commercialize NERLYNX® (neratinib) In Australia, New Zealand And South East Asia

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Specialised Therapeutics Asia, an international biopharmaceutical company with strategic focus and expertise in Australia, New Zealand and South East...

Puma Biotechnology's 5-Year Analysis Of Phase III ExteNET Study Published Online In The Lancet Oncology

Puma Biotechnology's 5-Year Analysis Of Phase III ExteNET Study Published Online In The Lancet Oncology

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the publication of previously presented results from the ExteNET Phase III clinical trial of Puma's drug neratinib in patients with early stage...

Puma Biotechnology Reports Third Quarter 2017 Financial Results

Puma Biotechnology Reports Third Quarter 2017 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter and nine months ended September 30, 2017.

Puma Biotechnology To Present At Stifel Healthcare Conference

Puma Biotechnology To Present At Stifel Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Secures $100 Million Term Loan From Silicon Valley Bank And Oxford Finance

Puma Biotechnology Secures $100 Million Term Loan From Silicon Valley Bank And Oxford Finance

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has entered into a loan agreement with Silicon Valley Bank, the bank of the world's most innovative companies and their investors, and Oxford Finance, a...

Puma Biotechnology To Present At Credit Suisse Healthcare Conference

Puma Biotechnology To Present At Credit Suisse Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology To Host Conference Call To Discuss Third Quarter Financial Results

Puma Biotechnology To Host Conference Call To Discuss Third Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

Short Interest In Puma Biotechnology Falls 51.2%

Short Interest In Puma Biotechnology Falls 51.2%

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 3,509,935 share decrease in total short interest for Puma Biotechnology Inc , to 3,338,965, a decrease of 51.25% since 09/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Noteworthy Wednesday Option Activity: PBYI, MBI, XON

Noteworthy Wednesday Option Activity: PBYI, MBI, XON

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Puma Biotechnology Inc , where a total volume of 6,609 contracts has been traded thus far today, a contract volume which is representative of approximately 660,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 89.5% of PBYI's average daily trading volume over the past month, of 738,030 shares.

Puma Biotechnology To Present At Cantor Fitzgerald Healthcare Conference

Puma Biotechnology To Present At Cantor Fitzgerald Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Presents 5-Year Analysis Of Phase III ExteNET Trial In Extended Adjuvant HER2-Positive Breast Cancer At ESMO 2017 Congress

Puma Biotechnology Presents 5-Year Analysis Of Phase III ExteNET Trial In Extended Adjuvant HER2-Positive Breast Cancer At ESMO 2017 Congress

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from the Phase III clinical trial of Puma's drug neratinib for the extended adjuvant treatment of early...

Puma Biotechnology To Participate In Panel Discussion At Citi's Biotech Conference

Puma Biotechnology To Participate In Panel Discussion At Citi's Biotech Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Announces Publication Of Abstracts For ESMO 2017

Puma Biotechnology Announces Publication Of Abstracts For ESMO 2017

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress,...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that on August 15, 2017 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit...

Puma Biotechnology Reports Second Quarter 2017 Financial Results

Puma Biotechnology Reports Second Quarter 2017 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2017.

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Jim Cramer is bullish on Philip Morris, 3M and Becton Dickinson; but he's bearish on Blue Apron and Puma Biotechnology.

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Jim Cramer says history doesn't have to repeat itself. You don't want to miss another opportunity in the highly visible FANG-style stocks.

Puma Biotechnology Receives Day-180 List Of Outstanding Issues From Committee For Medicinal Products For Human Use (CHMP)

Puma Biotechnology Receives Day-180 List Of Outstanding Issues From Committee For Medicinal Products For Human Use (CHMP)

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has issued its Day-180 List of Outstanding...

Puma Announces Availability Of NERLYNX™ (neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In The United States

Puma Announces Availability Of NERLYNX™ (neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In The United States

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that NERLYNX™ (neratinib) tablets, formerly known as PB272, is now commercially available by prescription in the United States.

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives

In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.

Puma Biotechnology Completes Targeted Enrollment In Neratinib Phase III Metastatic Breast Cancer Trial

Puma Biotechnology Completes Targeted Enrollment In Neratinib Phase III Metastatic Breast Cancer Trial

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that targeted patient enrollment in the Phase III NALA trial of the Company's lead drug candidate PB272 (neratinib) in patients with...

PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. to Contact The Firm

PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. to Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc.

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Puma Biotechnology, Inc. Shareholders And A Lead Plaintiff Deadline Of July 7, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc.

The Klein Law Firm Announces A Class Action Filed On Behalf Of Puma Biotechnology, Inc. Shareholders And A Lead Plaintiff Deadline Of July 7, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc.

TheStreet Quant Rating: D- (Sell)